Fed. Circ. Affirms Invalidity Of Bayer's Yasmin Patent

Law360, New York (August 5, 2009, 6:47 PM EDT) -- A federal appeals court has upheld a ruling that invalidated the patent for Bayer Schering Pharma AG's oral contraceptive Yasmin in a dispute with Barr Laboratories Inc. over a generic version of the drug.

In a 2-1 ruling, the U.S. Court of Appeals for the Federal Circuit found that the patent was invalid for obviousness, affirming a ruling that led Bayer to enter into a licensing agreement with Barr in mid-2008 to sell the generic product under its own label.

The patent-in-suit covers a method for...
To view the full article, register now.